Skip to main content
Healthcare

STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Feed excerpt — reported by STAT News

Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.